MXPA98002001A - Antagonists of receiver 5-th3 for discine - Google Patents
Antagonists of receiver 5-th3 for discineInfo
- Publication number
- MXPA98002001A MXPA98002001A MXPA/A/1998/002001A MX9802001A MXPA98002001A MX PA98002001 A MXPA98002001 A MX PA98002001A MX 9802001 A MX9802001 A MX 9802001A MX PA98002001 A MXPA98002001 A MX PA98002001A
- Authority
- MX
- Mexico
- Prior art keywords
- tremor
- pharmaceutically acceptable
- ondansetron
- methyl
- treatment
- Prior art date
Links
- 230000003042 antagnostic Effects 0.000 title description 3
- 239000005557 antagonist Substances 0.000 title description 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims abstract description 22
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims description 28
- 229960005343 Ondansetron Drugs 0.000 claims description 27
- 208000001187 Dyskinesias Diseases 0.000 claims description 23
- 206010044565 Tremor Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 9
- 201000006517 essential tremor Diseases 0.000 claims description 6
- 206010022520 Intention tremor Diseases 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 3
- FEROPKNOYKURCJ-ZDUSSCGKSA-N 4-amino-N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@@H]1C(CC2)CCN2C1 FEROPKNOYKURCJ-ZDUSSCGKSA-N 0.000 claims description 2
- WUKZPHOXUVCQOR-UHFFFAOYSA-N Azasetron Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims description 2
- 229950005951 Azasetron Drugs 0.000 claims description 2
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 claims description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical group C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 2
- 229960003727 Granisetron Drugs 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 229960003550 alosetron Drugs 0.000 claims description 2
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003413 dolasetron Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 claims description 2
- 229960003688 tropisetron Drugs 0.000 claims description 2
- FLZQKRKHLSUHOR-UHFFFAOYSA-N Alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims 1
- -1 5-methyl-lH-imidazol-4-yl Chemical group 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 102000035257 5-HT3 receptors Human genes 0.000 description 8
- 108091005518 5-HT3 receptors Proteins 0.000 description 8
- 208000002033 Myoclonus Diseases 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 8
- 201000001973 choreatic disease Diseases 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010008748 Chorea Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010043118 Tardive dyskinesia Diseases 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000002490 cerebral Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010061536 Parkinson's disease Diseases 0.000 description 3
- 206010073211 Postural tremor Diseases 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002151 myoclonic Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003252 repetitive Effects 0.000 description 3
- 230000001020 rhythmical Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SPKBYQZELVEOLL-GOOCMWNKSA-N 5-chloro-2,2-dimethyl-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3H-1-benzofuran-7-carboxamide Chemical compound C([C@H]1CC[C@@H](C2)N1C)C2NC(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-GOOCMWNKSA-N 0.000 description 2
- 210000001638 Cerebellum Anatomy 0.000 description 2
- 229940005501 DOPAMINERGIC AGENTS Drugs 0.000 description 2
- 206010014623 Encephalopathy Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- NUMKWGDDRWJQMY-UHFFFAOYSA-N Lurosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=C(F)C=CC=C43)C)CC2)=O)=C1C NUMKWGDDRWJQMY-UHFFFAOYSA-N 0.000 description 2
- 206010028334 Muscle spasms Diseases 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 208000009025 Nervous System Disease Diseases 0.000 description 2
- 206010029305 Neurological disorder Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- FEROPKNOYKURCJ-UHFFFAOYSA-N Zacopride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 2
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZEYGAOFLBIEQJQ-SPIKMXEPSA-N (Z)-but-2-enedioic acid;6-chloro-2-(4-methylpiperazin-1-yl)-3-propan-2-ylbenzimidazol-5-amine Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N=1C2=CC(Cl)=C(N)C=C2N(C(C)C)C=1N1CCN(C)CC1 ZEYGAOFLBIEQJQ-SPIKMXEPSA-N 0.000 description 1
- ZXHIYWJYTQDWAK-UHFFFAOYSA-N 1,7-dihydroindol-6-one Chemical compound C1=CC(=O)CC2=C1C=CN2 ZXHIYWJYTQDWAK-UHFFFAOYSA-N 0.000 description 1
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-M 1-carboxynaphthalen-2-olate Chemical class C1=CC=CC2=C(C([O-])=O)C(O)=CC=C21 UPHOPMSGKZNELG-UHFFFAOYSA-M 0.000 description 1
- RFXHBILZLMJCSN-JLYLLQBASA-N 1-cyclohexyl-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-4-oxoquinoline-3-carboxamide Chemical compound C([C@H]1CC[C@@H](C2)N1C)C2NC(=O)C(C(C1=CC=CC=C11)=O)=CN1C1CCCCC1 RFXHBILZLMJCSN-JLYLLQBASA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-M 1-naphthoate Chemical class C1=CC=C2C(C(=O)[O-])=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-M 0.000 description 1
- JKERXBZCPHYIGM-UHFFFAOYSA-N 2,3,3a,4,5,6-hexahydrobenzo[de]isoquinolin-1-one;hydrochloride Chemical compound Cl.C1CCC2=CC=CC3=C2C1CNC3=O JKERXBZCPHYIGM-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- ILXWRFDRNAKTDD-GOOCMWNKSA-N 3,3-dimethyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2H-indole-1-carboxamide Chemical compound C1C(C)(C)C2=CC=CC=C2N1C(=O)NC(C1)C[C@H]2CC[C@@H]1N2C ILXWRFDRNAKTDD-GOOCMWNKSA-N 0.000 description 1
- MZRKHUUDDHJVHS-MOKVOYLWSA-N 3-ethyl-N-[(5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxobenzimidazole-1-carboxamide Chemical compound C1C(N2C)CC[C@H]2CC1NC(=O)N1C2=CC=CC=C2N(CC)C1=O MZRKHUUDDHJVHS-MOKVOYLWSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- DBQMQBCSKXTCIJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-(cyclopropylmethoxy)benzamide Chemical compound C1N(CC2)CCC2C1NC(=O)C=1C=C(Cl)C(N)=CC=1OCC1CC1 DBQMQBCSKXTCIJ-UHFFFAOYSA-N 0.000 description 1
- RZYIIEGPJPMBOE-ZDUSSCGKSA-N 4-amino-N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2,3-dihydro-1-benzofuran-7-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1 RZYIIEGPJPMBOE-ZDUSSCGKSA-N 0.000 description 1
- SRYCADDCUWPWAE-UHFFFAOYSA-N 7-methyl-1H-indole-3-carboxylic acid Chemical compound CC1=CC=CC2=C1NC=C2C(O)=O SRYCADDCUWPWAE-UHFFFAOYSA-N 0.000 description 1
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000001183 Brain Injury Diseases 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- YCVLFIFJAANCME-UHFFFAOYSA-N C(N1CCN(CC1)c1cc2ccccc2[nH]1)c1ccc2OCOc2c1 Chemical compound C(N1CCN(CC1)c1cc2ccccc2[nH]1)c1ccc2OCOc2c1 YCVLFIFJAANCME-UHFFFAOYSA-N 0.000 description 1
- DBTJGFLNJVZYSI-UHFFFAOYSA-N C1=2C3=CC=CC=2CC=CN1C1=C3C(=O)C=CC1 Chemical compound C1=2C3=CC=CC=2CC=CN1C1=C3C(=O)C=CC1 DBTJGFLNJVZYSI-UHFFFAOYSA-N 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N CHEMBL2105109 Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- NCNFDKWULDWJDS-OAHLLOKOSA-N Cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 208000010118 Dystonia Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940079360 Enema for Constipation Drugs 0.000 description 1
- 206010015832 Extrapyramidal disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 208000010501 Heavy Metal Poisoning Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 229950007654 ITASETRON Drugs 0.000 description 1
- 210000001847 Jaw Anatomy 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 229950009334 LUROSETRON Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229950009727 Lerisetron Drugs 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium Ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical class COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229950007262 Mirisetron Drugs 0.000 description 1
- 208000006625 Myoclonic Epilepsy Diseases 0.000 description 1
- 208000002040 Neurosyphilis Diseases 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 229950006391 Pancopride Drugs 0.000 description 1
- 208000003715 Parkinsonian Disorders Diseases 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- ILXWRFDRNAKTDD-UHFFFAOYSA-N Ricasetron Chemical compound C1C(C)(C)C2=CC=CC=C2N1C(=O)NC(C1)CC2CCC1N2C ILXWRFDRNAKTDD-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 206010042258 Structural brain disease Diseases 0.000 description 1
- 206010042732 Sydenham's chorea Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229940064707 Sympathomimetics Drugs 0.000 description 1
- 208000005057 Thyrotoxicosis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000001203 Wilson disease Diseases 0.000 description 1
- 229950004681 Zacopride Drugs 0.000 description 1
- 229950001074 Zatosetron Drugs 0.000 description 1
- UBIAWBSPCYNXMC-QNBGGDODSA-N [(5S,6R)-4-(4-fluorophenyl)-1-azabicyclo[3.3.1]non-3-en-6-yl] propanoate;hydron;chloride Chemical compound Cl.C([C@H]([C@@H]1C2)OC(=O)CC)CN2CC=C1C1=CC=C(F)C=C1 UBIAWBSPCYNXMC-QNBGGDODSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960002099 cilansetron Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000001815 facial Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UAAKJEVCDBPTQS-UHFFFAOYSA-N methanesulfonic acid;dihydrate Chemical compound O.O.CS(O)(=O)=O UAAKJEVCDBPTQS-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000000701 neuroleptic Effects 0.000 description 1
- 230000004776 neurological deficiency Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- JDHUGVPBIIMGMO-UHFFFAOYSA-N octan-3-yl 1H-indole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC(CC)CCCCC)=CNC2=C1 JDHUGVPBIIMGMO-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical class NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000001975 sympathomimetic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The invention provides the use of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof for use in treating the disc
Description
ANTAGONISTS OF THE 5-HT3 RECEIVER FOR DISCINESIA
Field of the Invention
The invention relates to a new medical use for compounds that act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT3 receptors.
Background of the Invention
-HT3 receptor antagonists can be identified by methods well known in the art, for example, by their ability to inhibit 3 - (5-methyl-lH-imidazol-4-yl) -1- [1- [3H ] -methyl-lH-indol-3-yl] -1-propanone, which binds in the homogenates of the rat's entorinal cortex (following the general procedure described by G. Kilpatrick et al., Nature, 1987, 330. 746-748), and / or by its effect on the induced 5-HT reflex of Bezold-Jarisch (BJ) in the cat (following the general method described by A. Butler et al, Br. J. Pharmacol., 2 , 397-412 (1988)).
A variety of different 5-HT 3 receptor antagonists have been described, for example, those mentioned in the following patent applications (and hereinafter referred to as the compounds of Group A):
REF: 27019 AU619731 AU626614 AU8658939 AU8660274 AU8716591
AU8767121 EP067770 EP158265 EP158532 EP189002
EP190920 EP191562 EP200444 EP202062 EP210840
EP212802 EP214772 EP219193 EP220011 EP221702
EP230718 EP234872 EP23588 EP237281 EP239321
EP242973 EP254584 EP255297 EP261964 EP266730
EP266899 EP276163 EP287196 EP289170 EP291172
EP294292 EP297651 EP302699 EP306148 EP306323
EP307145 EP307172 EP309423 EP311724 EP313393
EP315316 EP315390 EP317088 EP322016 EP323077
EP327307 EP327335 EP328200 EP329932 EP330788
EP330824 EP336759 EP337547 EP338650 EP339669
EP339950 EP339959 EP344015 EP345956 EP350130
EP351385 EP353983 EP356098 EP357417 EP358903
EP361317 EP361629 EP375045 EP376624 EP377238
EP378111 EP381422 EP385722 EP387431 EP392663
EP393766 EP403261 EP403882 EP405784 EP407137
EP410509 EP419397 EP420086 EP429984 EP430190
EP436245 EP454121 EP456519 EP457243 EP458636
EP469449 EP482939 EP483836 EP485962 EP490263
EP491664 EP498466 EP554794 GB2125398 GB2145416
GB2152049 GB2153821 GB2169292 GB2192885 GB2208385
GB2208862 GB2213816 GB2216516 GB2225574 GB2229182
GB2236528 GB2236751 GB2247886 US4290227 US4486441
US4657911 US4789673 US4816453 US4822881 US4826838 US4857517 US4859683 US4914207 US4920219 US4921982
US4924010 US4935511 US4963689 US4992461 US4997956
US5030646 US5063230 US5116984 US5137893 O8403281 O8801866 O8909217 O9006309 O9101316 WO9104738 O9107402 09112254 09116888 W09117161 O9205174 O9206689 O9209284 W09212149;
all of which are incorporated here as a reference. The above applications also describe, in relation to the described 5-HT3 receptor antagonists, the appropriate methods of their preparation and the doses for their administration.
British Patent No. 2153821 B describes, inter alia, 1, 2, 3, 9-tetrahydro-9-methyl-3 - [(2-methyl-1H-imidazol-1-yl) methyl] -4H -carbazole-4-one, now known as ondansetron, which can be represented by the formula (I)
and pharmaceutically acceptable salts, solvates and pharmaceutically acceptable equivalents thereof.
Particular examples of the compounds within Group A include the compounds of Group B, particularly:
endo-N- (8-methyl-azabicyclo [3.2.1] oct-3-yl) 2,3-dihydro-2-oxo-lH-benzimidazole-i-carboxamide (itasetron); endo-N- (8-methyl-8-azabicyclo [3.2.1] oct-3-yl) 2,3-dihydro-3-ethyl-2-oxo-lH-benzimidazole-l-carboxamide (BIMU
1); endo-8-methyl-8-azabicyclo [3.2.1] oct-3-yl indole-3-carboxylate (tropisetron); endo-N- (9-methyl-9-azabicyclo [3.3.1] non-3-yl) -l-methylimidazol-3 -carboxamide (granisetron); trans-hexahydro-8- (3-indolylcarbonyloxy) -2,6-methano-2H-quinolizin-3 (4H) -one (dolasetron) preferably in the form of its mesylate; endo-5-chloro-2,3-dihydro-2,2-dimethyl-N- (8-methyl-8-azabicyclo [3.2.1] oct-3-yl) -7-benzofuran carboxamide (zatosetron); 4-amino-N- [1-azabicyclo (2.2.2) oct-3-yl] -5-chloro-2-methoxybenzamide (zacopride), more preferably (R) zacopride; 4- [N- (l-azabicyclo [2.2.2] octan-3- (5) -yl)] 2 -chloro-cis 5a- (s) -9a- (s) -5a, 6, 7, 8, 9,9a-hexahydrobenzofuran carboxamide (RG-12915);
4-amino-5-chloro-N- [2-pyrrolidylamethyl] -2,3-dihydrobenzo [b] furan-7-carboxamide (ADR-851); 4-amino-N- [1-azabicyclo [2.2.1] oct-3-yl] -5-chloro-2,3-dihydrobenzo [b] furan-7-carboxamide (ADR-882); (R) -5- [(1-methyl-3-indolyl) carbonyl] -4,5,6,7-tetrahydro-1H-benzimidazole (Y 060); (±) -N- (1-azabicyclo [2.2.2] oct-3-yl) -6-chloro-4-methyl-3-OXO-3,4-dihydro-2H-l, -4-benzoxazine-8 -carboxamide (azasetron); endo-N- (8-methyl-8-azabicyclo [3.2.1] oct-3-yl) -2,3-dihydro-3, 3-dimethyl-indole-1-carboxamide (BRL 46470); and 2,3,4,5-tetrahydro-5-methyl-2- [(5-methyl-1H-imidazol-4-yl) methyl] -lH-pyrido [4, 3-b] indol-1-one ( alosetron), preferably as its hydrochloride; 6-Fluoro-2,3,4,5-tetrahydro-5-methyl-2- [(5-methyl-1H-imidazol-4-yl) methyl] -lH-pyrido [4, 3-b] indole-1 -one (lurosetron), in particular in the form of mesylate dihydrate; 4H-pyrido (3.2, 1-jk) carbazole-11 (8H) -one, 5, 6, 9, 10-tetrahydro-10 ((2-methyl-lH-imidazol-1-yl) methyl-, ( R) - (cilansetron) benzamide, 4-amino-5-chloro-N- (8-methyl-8-azabicyclo (3.2.1) oct-3-yl) -2- ((1-methyl-2-butynyl) ) oxy) -, monohydrochloride, (3 (S) -endo) (E-3620);
irido (1, 2 -a) indole-6 (7H) -one, 8,9-dihydro-10-methyl-7- ((5-rt? ethyl-lH-imidazol-4-yl) methyl-, monohydrochloride, (+) - (FK-1052), benzamide, 4-amino-N-1-azabicicio (2.2.2.) Oct-3-il-5-chloro-2-cyclopropylmethoxy) -, (+/-) - ( pancopride), -and 8-methyl-8-azabicyclo (3.2.1) oct-3-yl ester of 7-methyl-1H-indole-3-carboxylic acid.
It will be appreciated by the skilled person that as a result of the use of different naming conventions of chemical products (eg, IUPAC, CA) a compound in group B can be referred to by a different chemical name within the corresponding patent application in Group A.
Other examples of 5-HT3 receptor antagonists, for use in accordance with the invention include the compounds of Group C, namely:
lH-indole, 2,3-dihydro-l- ((4,5,6,7-tetrahydro-lH-benzimidazol-5-yl) carbonyl) -, monohydrochloride, (R) - (YM-114); ÍH-Benzimidazole, 1- (phenylmethyl) -2- (1-piperazinyl) - (lerisetron);
endo-3,9-dimethyl-3,9-diazabicyclo (3.3.1) non-7-yl-lH-indazole-3-carboxamide dihydrochloride (N-3389); RS-25259; endo-8-methyl-8-azabicyclo (3.2.1) oct-3-yl-1-isobutyl-2-oxo-l, 2-dihydro-4-quinnuclidinecarboxylate (KF-18259); 2-methoxy-4-amino-5-chloro-N- hydrochloride (hexahydro-lH, 2,5-beta-methane-3 alpha, 6 alpha-cyclopenta (c) -pyrrol-4-alpha-4- (R) -yl benzamide (SC-52491); (3aS) - (2- ((S) -1-azabicyclo (2.2.2) oct-3-yl) -2, 3,3a, 4, 5, 6 hydrochloride hexahydro-lH-benz (de) isoquinolin-1-one; endo-1-Cyclohexyl-N- (8-methyl-8-azabicyclo (3.2.1) or an-3-yl) -4-oxo-1,4 -dihydroquinoline-3-carboxamide (mirisetron); 6-amino-5-chloro-1-isopropyl-2- (4-methyl-1-piperazinyl) benzimidazole dimaleate (KB-6933); hydrochloride of (+) - endo-4 - (propionyloxy) -6- (4-fluorophenyl) -1-azabicyclo (3.3.1) non-6-ene (GYKI-46903) and 3- (2- (4'-piperonylpiperazinyl) indole) carboxyaldehyde (VA-) 21B7).
The 5-HT3 receptor antagonists are known to be useful in the treatment of a variety of conditions involving 5-HT3 receptor mediation mechanisms, including in particular emesis.
Abnormal involuntary movements or dyskinesias include, inter alia, tremor, chorea (San Vito dance), myoclonus and tics. In addition to these categories of dyskinesia, there is a particular set of involuntary movements known as tardive dyskinesia or tardive dyskinesia induced by medications.
Tremor is an abnormal involuntary tremor or vibration. It can be characterized as a sinusoidal rhythmic movement of a part of the body caused by regular and rhythmic muscle contractions.
The chorea consists of a continuous flow of irregular, spasmodic and explosive movements that flit from one part of the body to another in a random sequence. Each contraction of the muscle is brief and often appears as a fragment of what could have been a normal movement, and is quite unpredictable in time or location.
Myoclonus consists of rapid muscle spasms such as shock, often repetitive and sometimes rhythmic.
Tics are similar to myoclonic spasms in appearance, but they are repetitive, stereotyped movements that can be imitated voluntarily and can be kept in check by an effort of will at the expense of mounting an internal tension.
Tardive dyskinesia is typically marked by repetitive involuntary movements of the facial, buccal, oral or cervical muscles.
Current medical therapies for dyskinesia, particularly where dyskinesia is the only feature of the disease (eg, benign (hereditary) essential and benign essential tremor (myoclonus)), include alcohol, benzodiazepines such as diazepam, lorazepam and clonazepam; and b-adrenergic receptor antagonists such as propranolol. Other dyskinesias are often a facet of another neurological disorder, and the treatment of dyskinesia follows that appropriate for the relevant neurological disorder. For example, the treatment of tremor caused by Parkinson's disease can be by dopaminergic agents such as levodapa and anitmuscarinic agents such as benzenexol.
However, many patients obtain little or no relief from such agents. In addition, the profiles of the side effects of these medications severely limit their clinical use. Thus, there is a real need to develop new medicines for the treatment of dyskinesia.
Description of the invention
Surprisingly, it has now been found that 5-HT3 receptor antagonists are also useful in the treatment of dyskinesia.
According to one aspect of the invention, therefore, a 5-HT3 receptor antagonist, or a pharmaceutically acceptable derivative thereof, is provided for use in the treatment of dyskinesia.
By "pharmaceutically acceptable derivative" is meant any pharmaceutically acceptable salt or solvate of a 5-HT 3 receptor antagonist, or any other compound, which upon administration to the patient, is capable of delivering (directly or indirectly) a 5-HT 3 receptor antagonist. HT3, or an active metabolite or residue thereof.
In a preferred aspect, the invention provides a Group A compound or a pharmaceutically acceptable derivative thereof, more preferably a group B compound or a pharmaceutically acceptable derivative thereof, for use in the treatment of dyskinesia.
In a further preferred aspect, the invention therefore provides ondansetron or a pharmaceutically acceptable derivative thereof, for use in the treatment of dyskinesia.
Suitable pharmaceutically acceptable salts of ondansetron include acid addition salts formed with organic or inorganic acids (for example, hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthates, p-toluenesulfonates, methanesulfonates, sulphamates, ascorbates, tartrates, salicylates, succinates, lactates, glutarates, glutaconates, acetates, tricarbalylates, citrates, fumarates and maleates), and solvates (for example hydrates) thereof.
In a preferred embodiment of the present invention, ondansetron is used in the form of its hydrochloride, more preferably its hydrochloride dihydrate.
In another preferred embodiment of the present invention, ondansetron is employed in the form of its free base.
It will be appreciated by those skilled in the art that ondansetron contains a chiral center (shown by * in formula (I)) and that ondansetron therefore exists in the form of optical isomers (ie, enantiomers). The invention includes all isomers of ondansetron and their pharmaceutically acceptable derivatives, including all tautomeric and optical forms and mixtures thereof, including racemic mixtures.
Each type of dyskinesia can be caused by a variety of diseases. It may be accompanied by other neurological deficiencies, or abnormal involuntary movements may occur isolated and constitute the disease. The 5-HT3 receptor antagonists are particularly useful in the treatment of tremor, chorea, myoclonus, tics and tardive dyskinesia.
The tremor includes tremor at rest, postural tremor, and intention tremor. The resting tremor may be caused by, for example, Parkinson's disease, post-encephalic parkinsonism, drug-induced parkinsonism and other extrapyramidal diseases. Postural tremor can be caused by, for example, physiological tremor; exaggerated physiological, tremor attributable to for example, thyrotoxicosis, anxiety states, alcohol, medications (such as sympathomimetics, antidepressants and lithium) and heavy metal poisoning (such as mercury); hyperthyroidism, structural brain disorder attributable to, for example, severe brain injuries, Wilson's disease and neurosyphilis; and benign (hereditary) essential tremor. The intention tremor can be caused by, for example, cerebellum or brainstem disease attributable to for example, multiple sclerosis (MS), spinocerebellar degenerations, vascular disorder and tumor.
Chorea includes Sydenham's chorea, Huntington's disease, benign hereditary chorea, symptomatic chorea, drug-induced chorea, and hemiballism (hemicorea).
Myoclonus includes generalized myoclonus, such as progressive myoclonic encephalopathies, static myoclonic encephalopathies, myoclonic epilepsies, benign (hereditary) essential myoclonus, and focal myoclonus
(segmental).
Tics include simple tics, complex multiple tics (eg, Gilles de la Tourette syndrome), and symptomatic tics.
Tardive dyskinesia may develop after the treatment of for example, psychotic disorders (such as schizophrenia and mania) with neuroleptics such as phenothiazines; and cognitive disorders such as dementia (eg, Parkinson's disease), with dopaminergic agents such as levodopa. Tardive dyskinesia may persist after withdrawal of treatment.
In a preferred aspect, the invention provides a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof, for use in the treatment of tremor.
In another preferred aspect, the invention provides a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof, for use in the treatment of benign (hereditary) essential tremor.
Benign (hereditary) essential tremor can occur at any age and is often inherited as an autosomal dominant characteristic. It is characterized by the postural tremor of the arms and head, although the jaw, tongue, legs and trunk may also be affected.
In a further preferred aspect, the invention provides a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof, for use in the treatment of intention tremor.
In another aspect, the invention provides a method of treating a mammal including man, who suffers from dyskinesia, which comprises the administration of an effective amount of the receptor antagonist or a pharmaceutically acceptable derivative thereof.
In another aspect, the invention provides the use of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of dyskinesia.
Within the above aspects and preferred aspects of the invention, the use of a Group A 5-HT3 receptor antagonist, more preferably a Group B 5-HT3 receptor antagonist, and most preferably ondansetron is most preferred.
It is understood that reference to treatment includes treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.
Conveniently, a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof, can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients. Thus, a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof may for example be formulated for oral, sublingual, buccal, parenteral, rectal or intranasal administration, or in a form suitable for administration by inhalation or insufflation (and either through the mouth or nose) or in a form appropriate for topical administration.
For oral administration, the pharmaceutical compositions can take the form of for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (eg, pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (eg lactose, microcrystalline cellulose or calcium phosphate); lubricants (eg, magnesium stearate, talc or silica); disintegrated (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be present as a dry product for constitution with water or other suitable vehicle before use. Said liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (eg, sorbitol syrup, methyl cellulose or edible hydrogenated fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (eg, almond oil, oily esters or ethyl alcohol); and conservatives
(e.g., propyl or methyl p-hydroxybenzoates or sorbic acid).
For oral administration the compositions may take the form of tablets or lozenges formulated in a conventional manner.
A 5-HT3 receptor antagonist, or a pharmaceutically acceptable derivative thereof, can be formulated for parenteral administration by injection, conveniently an intravenous, intramuscular or subcutaneous injection for example by bolus injection or continuous intravenous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, optionally with an added preservative.
Compositions for parenteral administration may take such forms as suspensions, solutions or emulsions in aqueous or oily vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Alternatively, the compositions may be in dry form such as a freeze-dried, crystalline or solid powder for constitution with an acceptable carrier, eg, sterile, pyrogen-free water or isotonic saline before use. They can be presented, for example, in sterile vials or vials.
A 5-HT3 receptor antagonist, or a pharmaceutically acceptable derivative thereof can also be formulated in rectal compositions such as suppositories or retention enemas.
Tablets for sublingual formulation can be formulated in a conventional manner.
For intranasal administration, or administration by inhalation or insufflation, a 5-HT 3 receptor antagonist, or a pharmaceutically acceptable derivative thereof can be formulated in a conventional manner.
For topical administration, the pharmaceutical compositions can be liquid, for example solutions, suspensions or emulsions presented in the form of creams or gels.
In addition to the formulations previously described, a 5-HT 3 receptor antagonist, or a pharmaceutically acceptable derivative thereof can also be formulated as a depot preparation. Such extended-action formulations can be administered by implantation (for example subcutaneously, transcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compositions can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or poorly soluble derivatives for example, a sparingly soluble salt.
Pharmaceutical formulations of ondansetron or a pharmaceutically acceptable derivative thereof can be prepared, for example, according to British Patent UK No. GB 2153821B, the publication of European Patent Application No. 276559 or the Publication of International Patent Applications Nos. 094/27599, 096/15785 or W096 / 15786.
It will be appreciated that the precise therapeutic dose of a 5-HT3 receptor antagonist, expressed in the form of its free base, will depend on the age and condition of the patient and the nature of the dyskinesia to be treated, and will ultimately be at the physician's discretion. to attend him
However, in general, effective doses for the treatment of dyskinesia, in particular tremor, will be in the range of 0.001 to 500 mg, such as 0.01 to 100 mg, preferably 0.05 to 50 mg, for example 0.5 to 25 mg per unit dose, which could be administered in single or divided doses, for example, from 1 to 4 times a day.
In a preferred embodiment, the effective doses of ondansetron for tremor treatment will be in the range of 0.05 to 100 mg, such as 0.1 to 50 mg, preferably 0.5 to 25 mg, for example 2, 4, 8 or 16 mg of ondansetron per unit dose, which could be administered in single or divided doses, for example, from 1 to 4 times a day.
The use of ondansetron in the treatment of dyskinesia is supported in the following clinical data.
A double-blind, placebo-controlled, crossover study of intravenous ondansetron was performed in twenty patients with cerebellar tremor caused by MS, cerebellar degeneration, or drug toxicity.
Most had tremor based on cerebellar involvement from the MS, three had hereditary degenerative disorders involving the cerebellum and one had acquired lithium toxicity. The clinical information and the previous treatment of patients is detailed below in Table 1.
Patients were randomly assigned to receive intravenous ondansetron (8 mg or a placebo, consisting of normal saline). The medication was given by an intravenous bolus injection. The patients were given an alternate agent at a later interval.
The main output measure was the change in manual coordination tasks as assessed by spiral copying, copying words or line drawing, and the time to complete a nine-hole grade test. Only 12 patients had sufficient coordination to complete the nine-hole grade test.
Clinical response was measured at baseline and one hour after infusion.
Figures 1 (a), (b) and (c) represent an attempt to copy a spiral by the first patient mentioned in Table 1. Figure 1 (a) represents an attempt prior to treatment with ondansetron; Figure 1 (b) an attempt after receiving the placebo and Figure l (c) an attempt after receiving the ondansetron.
Resul ates The patient profile and clinical responses are shown in Table 1
Table 1
Keys: The improvement was measured on a simple ordinary scale: 0 = none, + = a little, ++ = moderate, +++ = too much improvement The spiral writing of this patient is shown in Figure 1 (a), 1 (b) and 1 (c); 2 The development of dystonia in this patient dissipated the enthusiasm to continue in the study; Cd = cerebellar degeneration
A favorable clinical response was identified by a panel of three blind observers in 13 of 20 patients; the same observers identified a response in a patient treated with placebo. The difference was important in the complete study group (p = 0.009, Fisher's exact relation) and the MS subgroup of 16 patients, 13 of which had a response (p = 0.001).
At the completion of the scheduled task, the nine-hole grade test, patients receiving ondansetron were improved. The average time for completion of this task was 79 ± 13 (standard error) seconds in patients treated with ondansetron and 87 ± 12 seconds in patients treated with placebo (p = 0.04; Mann Whitney; an end test for even data ). An additional patient with cerebellar degeneration, also disabled to complete these tasks (Cd2, Table 1), was observed to have improved speech after treatment with ondansetron.
Patient identification of the treatment allocation was correct in 12/20 cases and this was based on efficacy. No one believed that the placebo was better (p = 0.014, Fisher's exact ratio).
The recruitment of patients was biased to select the most severely challenged patients: Most patients required walking assistance. After the study was completed, it was apparent that the best responses were seen in the least disabled patients. Among patients with MS, a better response was observed in patients with onset of more recent ataxia.
Ondansetron was well tolerated and the effect could be sustained in the long term. The withdrawal of the medication resulted in the tremor returning to pre-study levels. Nothing worked well for the tremor in these patients before the use of ondansetron.
The effect of intravenous ondansetron could be reproduced with oral ondansetron (8-16 mg).
It is noted that with respect to this date, the best method known to the applicant to carry out the invention is that which is clear from the present description of the invention.
Having described the invention as above, the content of the following is claimed as property
Claims (10)
1. The use of a 5-HT3 receptor antagonist, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of dyskinesia.
2. The use according to claim 1, characterized in that the dyskinesia is tremor.
3. The use according to claim 2, characterized in that the tremor is a benign (hereditary) essential tremor.
4. The use according to claim 2, characterized in that the tremor is an intention tremor.
5. The use according to any of claims 1-4, characterized in that the 5-HT3 receptor antagonist is ondansetron or a pharmaceutically acceptable derivative.
6. The use according to claim 5, characterized in that ondansetron is in the form of its hydrochloride or dihydrate hydrochloride.
7. The use according to claim 5, characterized in that the ondansetron is in the form of its free base.
8. The use according to any of claims 1-4, characterized in that the 5-HT3 receptor antagonist is selected from granisetron, tropisetron, azasetron, dolasetron, alosetron or (R) zacopride.
9. A method for the treatment of a mammal, including man, suffering from dyskinesia, characterized in that it comprises the administration of an effective amount of a 5-HT 3 receptor antagonist, or a pharmaceutically acceptable derivative thereof.
10. A 5-HT3 receptor antagonist, or a pharmaceutically acceptable derivative thereof for use in the treatment of dyskinesia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9519021.1A GB9519021D0 (en) | 1995-09-18 | 1995-09-18 | Medicaments |
GBGB9519029.4A GB9519029D0 (en) | 1995-09-18 | 1995-09-18 | Medicaments |
GB9519029.4 | 1995-09-18 | ||
GB9519021.1 | 1995-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9802001A MX9802001A (en) | 1998-10-31 |
MXPA98002001A true MXPA98002001A (en) | 1999-01-11 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5225407A (en) | 5-HT3 receptor antagonists for the treatment of autism | |
US10548855B2 (en) | Memantine combinations and use | |
SK281603B6 (en) | Use of serotonin antagonists (5ht3) for treating fibromyalgia | |
EP0340270B1 (en) | 5-ht 3? receptor antagonists for treatment of cough and bronchoconstriction | |
WO2002036113A1 (en) | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) | |
WO2002036114A1 (en) | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 | |
WO2018039159A1 (en) | Muscarinic m2-antagonist combination | |
WO2012002583A1 (en) | Method for treating schizophrenia and related diseases with a combination therapy | |
EP0450757A2 (en) | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood | |
EP0851756B1 (en) | Use of ondansetron in the manufacture of a medicament for the treatment of tremor | |
MXPA98002001A (en) | Antagonists of receiver 5-th3 for discine | |
WO2001095903A1 (en) | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction | |
WO2001095902A9 (en) | A composition comprising a combination of receptor agonists and antagonists | |
US5198447A (en) | Medicaments | |
KR100829297B1 (en) | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | |
Oakley et al. | 5-HT 3 receptor antagonists for the treatment of autism | |
JPWO2003018012A1 (en) | Constipation type IBS prophylactic / therapeutic agent | |
KR20010071893A (en) | Method of Treatment | |
MXPA01000466A (en) | Method of treatment | |
PL197982B1 (en) | Application of optically pure (S,S)-reboxetine and the pharmaceutically acceptable salts thereof for drug preparation |